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Abstract
Purpose—To develop accurate in silico predictors of Plasma Protein Binding (PPB).
Methods—Experimental PPB data were compiled for over 1,200 compounds. Two endpoints 
have been considered: (1) fraction bound (%PPB); and (2) the logarithm of a pseudo binding 
constant (lnKa) derived from %PPB. The latter metric was employed because it reflects the PPB 
thermodynamics and the distribution of the transformed data is closer to normal. Quantitative 
Structure-Activity Relationship (QSAR) models were built with Dragon descriptors and three 
statistical methods.
Results—Five-fold external validation procedure resulted in models with the prediction accuracy 
(R2) of 0.67±0.04 and 0.66±0.04, respectively, and the mean absolute error (MAE) of 15.3±0.2% 
and 13.6±0.2%, respectively. Models were validated with two external datasets: 173 compounds 
from DrugBank, and 236 chemicals from the US EPA ToxCast project. Models built with lnKa 
were significantly more accurate (MAE of 6.2–10.7%) than those built with %PPB (MAE of 11.9–
17.6%) for highly bound compounds both for the training and the external sets.
Conclusion—The pseudo binding constant (lnKa) is more appropriate for characterizing PPB 
binding than conventional %PPB. Validated QSAR models developed herein can be applied as 
reliable tools in early drug development and in chemical risk assessment.
Keywords
machine learning; %PPB; drug fraction bound; ADMET; pharmacokinetics
§Address correspondence to Shushen Liu, 417 Mingjing Building, Tongji University, Shanghai, 200092 China. Telephone: (86) 21 
65982767. Fax: (86) 21 65982767. ssliuhl@263.net. **Address correspondence to Alexander Tropsha, 100K Beard Hall, University of 




Pharm Res. Author manuscript; available in PMC 2015 March 18.
Published in final edited form as:














Many small molecules, such as drugs and drug-like compounds in blood circulation form 
complexes with plasma proteins. The affinity of drugs to plasma proteins varies 
tremendously directly affecting the free drug concentration and pharmacokinetics. (1) 
Typically, the drug - plasma protein complex serves as a drug reservoir while the drug is 
eliminated from the body. (2) Accurate assessment of small molecules’ binding to plasma 
proteins is necessary for all aspects of ADME-Tox (absorption, distribution, metabolism, 
excretion, toxicity) (3) in the context of both drug discovery and in chemical risk 
assessment. (4)
Human plasma proteins are made up of albumin and globulin among which the human 
serum albumin, alpha-1-acid glycoprotein, and lipoproteins are the most abundant. (5) 
Experimentally, rapid equilibrium dialysis (RED) is a conventional method to determine a 
drug bound to plasma proteins (6) in a simulated in vivo environment (e.g., protein 
composition and concentration, body temperature etc.). However, RED and other techniques 
can still be time-consuming and expensive if applied to every candidate compound in the 
early drug discovery stage.
As one of the most efficient computational tools, Quantitative Structure-Activity 
Relationships (QSAR) modeling is widely applied to find statistical relations between 
chemical structural features and a particular biological activity. There have been several 
attempts to correlate experimental plasma protein binding values with chemical structural 
features. Hall et al. (7) modeled the binding of 115 beta-lactams to human plasma proteins 
using multiple linear regression resulting in a model with mean absolute error (MAE) in ten-
fold cross-validation of 10.9%. Lobel et al.(8) reported models with R2 (coefficient of 
determination) of 0.68 and 0.51 for training (226 compounds) and test (94 compounds) sets, 
respectively. Yamazaki et el. (9) developed nonlinear regression models for a set of 300 
compounds using pH-dependent octanol-water partition coefficient (LogP) as 
physicochemical parameters, resulting in R2 of 0.83 for an external validation set of 20 
compounds. Votano et al. (10) compiled a diverse dataset of about 1,000 drugs and drug-like 
compounds with experimental plasma protein binding values. In their study, artificial neural 
network and support vector machine (SVM) modeling yielded the lowest MAE value of 
14.1% and the highest MAE value of 18.3%, respectively, for a validation set of 200 
compounds. (For a detailed review of those studies please see the report of Hall et al. (11)). 
Moreover, since the 3D crystal structure of human serum albumin (HSA) is available, 
structure-based modeling strategies have been employed as well. (12) However, mostly due 
to multiple possible binding sites on HSA, earlier studies were usually limited to small sets 
of specific chemicals (13) often lacking rigorous external validation. Furthermore, earlier 
studies lacked special emphasis on accurately predicting highly bound compounds 
(11,14,15), which is highly important because strong plasma protein binding (90~100%) is 
often a desirable property in pre-clinical drug screening. (14)
In this study, a set of 1,242 compounds with known %PPB was compiled and curated from 
public sources. To our knowledge, this is the largest human plasma protein binding dataset 
available publicly. Using this dataset, QSAR models were developed and externally 
Zhu et al. Page 2













validated. In addition, a set of 173 compounds from DrugBank, and a set of 236 ToxCast 
chemicals with %PPB values measured using high-throughput screening bioassays were also 
used to validate our models.
MATERIALS AND METHODS
Modeling Dataset
A set of 1,242 unique compounds with known %PPB (see Supplementary Material Table 
S4) was compiled and curated from two major sources: the work of Votano et al. (10) and 
the database for pharmacokinetic properties. (16) According to the activity histogram (see 
Supplementary Material Fig. S1), the distribution of original %PPB values is heavily 
skewed toward highly bound range. We have transformed %PPB into a pseudo-equilibrium 
constant parameter (lnKa) and observed that the distribution of transformed values became 
normal-like (see Supplementary Material Fig.S1). The transformation equation (Eq. 1) (for 
derivation, see Supplementary Material Equations SE. 1–7) is given below:
Eq. 1
Where fb is %PPB × 0.01, and C is a constant set to 0.5. Note that similar transformations 
have been utilized in previous studies (2,8,11), but the ensuing advantages were not fully 
explored or discussed.
DrugBank Dataset
A set of drugs or drug-like compounds was curated from DrugBank v3.0 (http://
www.drugbank.ca/) that contains plasma protein binding data in a textual form, often as a 
range of values or a qualitative description. After transforming these into numerical %PPB 
values, we obtained a set of 173 unique compounds not present in the modeling dataset (see 
Supplementary Material Table S5).
ToxCast Dataset
A set of 236 unique chemicals with %PPB values measured in a high-throughput screening 
assay by Wetmore et al. (17)(18) was obtained from the US EPA ToxCast Phase I project. 
The ToxCast chemicals are mainly pesticides and were not present in our modeling dataset 
(see Supplementary Material Table S6).
Chemical Structure Curation
Chemical structures of all employed compounds were curated according to our standard 
procedure described elsewhere. (19) Briefly, canonical SMILES code for all compounds was 
generated by ChemAxon Standardizer (v.5.3, ChemAxon, Budapest, Hungary) to normalize 
chemotypes (neutralization, tautomerization, aromatization, 2D structure cleaning, counter-
ions removal) and to remove duplicate structures.
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A set of chemical descriptors annotated as “two-dimensional” was calculated using Dragon 
(v.5.5, Talete SRL, Milan, Italy). It comprises constitutional and topological descriptors, 
walk and path counts, connectivity indices, 2D autocorrelations, edge adjacency indices, 
Burden eigenvalues, topological charge indices, eigenvalue-based indices, functional group 
counts, atom-centered fragments, molecular properties, and 2D fingerprints. All descriptors 
were range-scaled to [0, 1] interval. We then removed descriptors with low variance 
(standard deviation < 0.001) or with high redundancy (if pairwise R2 > 0.90, one of the pair 
was randomly removed). A final set of 880 Dragon descriptors was used for QSAR 
modeling and for the estimation of structural diversity. The modeling dataset, with average 
pairwise Tanimoto similarity coefficient of 0.58 (see Supplementary Material Fig. S2), is 
chemically diverse and should have substantial coverage of the chemical space.
k Nearest Neighbors (kNN)
This method employs the k nearest neighbors’ prediction principle with a variable selection 
procedure. (20) In this study, a genetic algorithm was used to drive the variable selection 
(with a population consisting of 500 solutions, each ranging from 5 to 40 descriptors). The 
models were evaluated by internal leave-group-out cross-validation (LGO-CV) where a 
fraction of compounds (~ 20%) is removed from the modeling set and their biological 
activity was predicted as the weighted average of k nearest molecular (k was varied from 1 
to 6). Individual models were considered acceptable if their LGO-CV R2 was greater than 
0.60.
Random Forest (RF)
Random Forest is an ensemble of unpruned classification or regression trees created on 
bootstrap samples of the training data and random subsets of descriptors (mtry) for tree 
induction. (21) In this study, we used regression RF with the default parameters (number of 
trees = 500 and one-third of the total number of descriptors for mtry). (22)
Support Vector Machine (SVM)
The SVM regression approach finds in the descriptor-activity space the narrowest band 
containing most of the data points. In this study, we used LIBSVM with RBF kernel and the 
grid-search to optimize its cost and gamma parameters. (23)
Applicability Domain (AD)
To avoid over-extrapolation of activity prediction, a global AD is introduced (Eq. 2) to 
control the distance between a predicted compound and its closest neighbor in the training 
set (should be less than DT)
(2)
Here, ȳ and σ characterize the training set and are, respectively, the average and standard 
deviation of the Euclidean distances between each compound and its nearest neighbor. Z is a 
user-controlled threshold, which in this study was varied from to 0.5 to 3.0. (24,25)
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Y-randomization is carried out to establish model’s robustness. (26) The process consists of 
randomly shuffling activity values of the modeling set multiple times and rederiving models 
with these shuffled values; the “random” model performance is then evaluated using both 
training and test sets. This procedure was repeated five times and the one-tailed t-test p-
value was calculated, which is the probability to obtain random models with R2ext as high as 
models built with real activities. If the “p-value < 0.05” condition is not satisfied, models 
built with the real data are deemed unreliable.
Modeling and Validation
QSAR models were developed following our standard modeling workflow (27) using %PPB 
and lnKa as target endpoints (Fig. 1). Briefly, according to the five-fold external cross-
validation (5FCV) procedure, the modeling dataset was randomly split into five subsets of 
nearly equal size. Four of these were used for developing models and the remaining one - for 
the external validation of the models. This procedure was repeated five times till each of the 
five subsets served as a validation set once. The above procedure results in five sets of 
models (one for each fold) that are then used collectively for screening additional external 
sets; both the DrugBank and ToxCast chemicals were used to validate the external predictive 
power of our models. The prediction results of the lnKa models were converted back to 
fraction bound to facilitate the comparison between two endpoint representations.
RESULTS AND DISCUSSION
QSAR models based on both modeling target endpoints (i.e., %PPB and lnKa) were 
developed using three modeling approaches (kNN, RF, and SVM). All the prediction results 
were converted into fraction bound (%PPB) for proper comparison. We investigated the 
effect of varying the threshold value of the AD (Z-parameter from 0.5 to 3, Eq.2) on the 
chemical space coverage and prediction accuracy of our models. We found that different AD 
thresholds yield result with nearly the same prediction accuracy, while the coverage drops 
significantly (see Supplementary Material Table S1). Thus, all the statistical results listed 
were based on the largest AD (Z=3). Five-fold external cross-validation prediction 
performance for the modeling dataset of 1,242 curated compounds is summarized in Table I. 
Our five-fold external cross-validation yielded MAEs of 15.8–16.3% for %PPB models (i.e., 
those developed using %PPB as the modeling endpoint) and MAEs of 14.2–14.5% for lnKa 
models (Table I). All models developed with real data were found to have significantly 
better statistical characteristics (cf. Table I) than Y-randomized models (MAE=35.1–36.9, 
R2=0.001–0.002, n=5). Consensus prediction was calculated as the average prediction of the 
models built using RF, kNN, and SVM methods. It was slightly better (MAE for lnKa 
models is 13.6±0.8%) than individual models. These statistical results are comparable or 
better than those reported previously (11), while based on a larger database size.
Additional Validation of Models
Two datasets (DrugBank and ToxCast chemicals) were used for additional external 
validation to verify the predictability of our models (see Fig. 1). Since the protein binding of 
some DrugBank compounds is reported as a range or even as a qualitative description, we 
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represented those compounds in accordance with their original descriptions (e.g., intervals) 
when comparing with predicted values (Fig. 3). The prediction error for the set of 236 
ToxCast chemicals compounds is higher than that of the DrugBank compounds (Table I). 
This difference in validation performance might be due to different measuring method 
employed. The protein binding values for the set of 173 DrugBank drug or drug-like 
compounds were measured using the same conventional methods as the data in the modeling 
dataset. In contrast, the fraction bound of ToxCast chemicals was measured using high-
throughput screening technique (28), which is different from the conventional methods such 
as equilibrium dialysis. The experimental variance of conventional methods were estimated 
to be 0.01~10.3% for various compounds (6), which can be used as the estimation of the 
lowest prediction error we can ever expect from modeling such data. However, the 
experimental variance for the ToxCast chemicals is not available.
Comparison between Two Representations of the Plasma Protein Binding Values
As shown in Table I, lnKa models outperform %PPB models on the modeling data and on 
two external validation sets. To analyze the distribution of prediction errors further, we 
plotted MAE values as a function of experimental PPB% values (represented by 10 activity 
bins) for each of the three datasets (Fig. 2). For the modeling dataset (1,242 compounds), the 
lnKa models outperform the %PPB models for the low (%PPB < 30%) and relatively high 
(%PPB > 80%) protein binding (~700 compounds in both), while the %PPB models 
outperform the lnKa models for the medium binding range (%PPB=30–80%; ~400 
compounds) (Fig. 2A). The prediction errors for the DrugBank (Fig. 2B) and ToxCast (Fig. 
2C) chemicals show a similar trend.
Although there is no unanimous quantitative definition of the highly bound fraction, here we 
used “%PPB> 90%” as such, which is the same as FDA’s definition in its draft guideline on 
hepatic impairment. (29) Consequently, 469 out of 1,242 curated compounds in the 
modeling dataset were defined as highly bound and their cross validated MAEs were 12.9% 
and 7.6% for %PPB models and lnKa models, respectively. Likewise, the MAEs of 74 
highly bound DrugBank chemicals were 11.9% and 6.2% for %PPB and lnKa models and 
the MAEs of 156 highly bound ToxCast chemicals were 17.6% and 10.7% for %PPB and 
lnKa models. That is, for the five-fold external cross-validation and two additional 
validation cases, the prediction error for highly bound compounds was significantly lower (p 
< 0.01 by permutation test; n=10,000) for lnKa models.
This performance difference for the two representations of the target endpoints can be 
further emphasized by classifying compounds into three categories and then by examining 
the prediction accuracy for each category. We defined “weakly bound” category as %PPB < 
32%, “bound” category as %PPB from 32% to 90%, and compounds with fraction bound ≥ 
90% as “highly bound”. Our scheme is a modified version of the scheme by Saiakhov et al. 
(30), where %PPB >32% was defined as “bound”, %PPB<19% as “non-bound”, and in-
between values as “intermediate”. The Classification accuracy for each category and overall 
correct classification rate (CCR) for both %PPB models and lnKa models are shown in 
Table II (see also Supplementary Material Table S2). The prediction accuracy of the lnKa 
models for the highly bound categories exceeds that of %PPB models by 20–40% and for 
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weakly bound – by 10–27%, while for the medium category %PPB models have higher 
accuracy by about 20%. When lnKa is used instead of %PPB as the modeling endpoint, the 
overall CCR increases by 7.5%, 8.8%, and 11.6% for the DrugBank, ToxCast, and modeling 
sets respectively.
Superior prediction accuracy of lnKa models for highly-bound compounds has important 
practical implications, because many of the prescribed drugs fall into that group. (31) Small 
changes in fraction bound for those drugs may cause large changes in their free 
concentration in vivo. (15) Furthermore, in an in vivo system, a compound with high fraction 
bound will have a low plasma concentration which leads to its slower clearance and longer 
half-life time. (31) Therefore, prediction errors for highly bound drugs will have larger 
impact on the subsequent estimation of their in vivo pharmacokinetic parameters. Our results 
indicate that the lnKa models reported in this study are more suitable for practical ADMET 
calculations than previously reported models. (7,10,30)
Interpretation of QSAR Models
Interpretation of QSAR models in terms of the important chemical features can be useful for 
designing new drug candidates with desired properties. We ranked descriptors by their 
importance in our lnKa kNN and RF models. For ranking, in case of kNN, we used 
descriptor frequency of occurrence in the individual models of the kNN ensemble. (32,33) In 
case of RF, we used the mean decrease in accuracy after random permutations of 
descriptor’s values, which can affect multiple decision trees of the forest. (22) Ranked top 
10 descriptors for each of the kNN-lnKa and RF-lnKa models are shown in Supplementary 
Material Table S3 and six out of them (ALOGP, ALOGP2, MLOGP, BLTA96, Ui and 
nBM) are actually present in both lists. Lipophilicity is considered a major determinant of 
nonspecific protein binding (10,34), and indeed our results demonstrate that values of 
descriptors representing octanol-water partition coefficient (i.e., ALOGP, ALOGP2, and 
MLOGP) are higher for strong binders than for weak binders (see Supplementary Material 
Fig. S3). Furthermore, the same trend is observed for descriptors representing unsaturated 
bonds (i.e., Ui and nBM) and, by extension, hydrophobicity (see Supplementary Material 
Fig. S3).
Compounds Mispredicted by Individual Models
In effort to understand limitations of the models it is helpful to analyze compounds with 
large prediction errors. There were 76 compounds with prediction errors large than 40 
%PPB (Fig. 4 and Supplementary Material Table S7). However, the average MAE of their 
corresponding nearest neighbors is only 14.3%. Table III shows five examples from that list. 
The predicted %PPB values for azatadine, tilidine, sisomicin, cilazapril, and fluconazole are 
different from their corresponding experimental values, but close to the experimental and 
predicted %PPB of their individual nearest neighbors (cyclobenzaprine, methadone, 
netilmicin, quinapril, and voriconazole, respectively). The pairs of similar compounds with 
large difference in activity (so-called “activity cliffs”) present challenges for QSAR model 
development (35); they can also point to data errors, when structures or activity values are 
wrong. During the dataset curation, we found compounds with contradictory %PPB values 
reported in different literature sources. For example, the fraction bound of biotin was 
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reported as 80% in one publication (10), but 20% in another. (36) When we checked the 
original experimental work, we found that “approximately 12% of total biotin in plasma is 
covalently bound, 7% is reversibly bound, and 81% is free”. (36) It is obvious that free 
biotin fraction was mistaken as bound in the first source. On the other side, there are also 
some compounds that are likely to be true activity outliers. For example, the experimental 
%PPB value for fluconazole was reported as 21.2%, 21.8%, and 11% by three different 
measuring methods. (6) However its predicted %PPB is 66.1%, which is close to that of its 
nearest neighbor of voriconazole (Table III, (37,38)). This discrepancy could be due to 
specific interactions of fluconazole that are missed by our models; hence, additional data on 
similar compounds may be needed to update the models.
CONCLUSION
In this study, we curated the largest publicly available plasma protein binding dataset and 
developed predictive QSAR models that were rigorously validated on diverse external sets 
containing both, drugs and industrial chemicals. We compared the results of modeling 
plasma protein binding using two modeling target endpoints: fraction bound (i.e., %PPB) 
and lnKa (“binding constant”-like parameter). We found that lnKa models achieve higher 
prediction accuracy for highly bound compounds: The MAEs were 7.6%, 6.2% and 10.7% 
for the highly bound compounds in the modeling dataset, DrugBank, and ToxCast, 
respectively. The computational models developed in this study can accurately predict 
plasma protein binding of new chemicals, especially so for suspected strong binders, which 
is crucial for practical ADMET applications. Therefore, models developed herein can serve 
as useful virtual screening tools in human health risk assessment (for example, for 
toxicokinetic adjustment of estimated levels of exposure) and in early drug development. All 
models developed in this study are available for open access at our Chembench web-server 
(http://chembench.mml.unc.edu).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
%PPB Percent plasma protein binding
5FCV 5-fold external cross-validation
AD Applicability domain
ADMET Absorption, distribution, metabolism, excretion, and toxicity
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CCR Correct classification rate (balanced classification accuracy)
HSA Human serum albumin
kNN k nearest neighbors
lnKa Natural logarithm of the pseudo binding constant imputed from %PPB
LogP Octanol-water partition coefficient
LOO-CV Leave-one-out cross validation
MAE Mean absolute error
QSAR Qualitative structure-activity relationship
R2 Coefficient of determination
RED Rapid equilibrium dialysis
RF Random forest
RMSE Root mean square error
SVM Support vector machine
Tc Tanimoto similarity coefficient
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Plasma protein binding modeling workflow based on five-fold external cross-validation and 
additional validation on DrugBank and ToxCast chemicals; %PPB and lnKa models are 
QSAR models of %PPB and lnKa endpoints, respectively
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Distribution of mean absolute errors (MAE) of %PPB models (black bars) and lnKa models 
(red bars) predictions for 1,242 modeling set compounds (A), 173 DrugBank compounds 
(B), and 236 ToxCast chemicals (C). Predictions for each endpoint are based on the 
consensus of respective kNN, RF, and SVM models
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Prediction results for 173 DrugBank compounds based on the overall consensus of %PPB 
and lnKa models. Data points with experimental %PPB reported as a range are shown as 
blue bars and circles; unfilled black circles - %PPB reported as exact values; filled black 
circles – qualitative reports; down- and upward pointing red triangles – %PPB reported as 
“less than x” or “greater than x” values, respectively. Gray diagonal corresponds to y=x 
correlation line (R2=0.67). Blue diagonals are 30% off-sets from experimental %PPB values
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QSAR modeling results for the 5 fold cross-validation dataset of 1,242 compounds based on 
consensus prediction of lnKa models (RF, kNN, and SVM). Gray diagonal corresponds to 
y=x correlation line (R2=0.65). Red diagonals are 40% off-sets (red lines) from experimental 
%PPB values, Red dots represent 76 compounds with large prediction errors (MAE > 40%), 
their corresponding nearest neighbors (green diamonds) have average MAE of 14.3%
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